SCHEMBL3174479

SCHEMBL3174479

CCOC(=O)N1CCC(NC=O)CC1

nearest known ligand 0.67

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 2/20 0.67
THRB P10828 1/20 0.67
ATM Q13315 1/20 0.67
GAA P10253 1/20 0.54
MEN1 O00255 1/20 0.51
KMT2A Q03164 1/20 0.51
NOS2 P35228 3/20 0.50
LMNA P02545 1/20 0.49
POLB P06746 1/20 0.49
MAPK1 P28482 1/20 0.49
NOS3 P29474 2/20 0.48
ALDH1A1 P00352 2/20 0.48
NOS1 P29475 1/20 0.48
KDM4E B2RXH2 1/20 0.48
CHRM2 P08172 1/20 0.47
CHRM5 P08912 1/20 0.47
CHRM3 P20309 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14368354 0.94 L3MBTL1 (0.60) L3MBTL1THRBATMGAAMEN1
SCHEMBL6582665 0.86 LMNA (0.52) L3MBTL1THRBATMGAAMEN1
SCHEMBL20458886 0.85 THRB (0.60) L3MBTL1THRBATMGAAMEN1
SCHEMBL770649 0.84 EPHX1 (0.47) L3MBTL1THRBATMALDH1A1
SCHEMBL1487940 0.81 THRB (0.68) L3MBTL1THRBATMGAAMEN1
SCHEMBL1487944 0.81 THRB (0.68) L3MBTL1THRBATMGAAMEN1
SCHEMBL14476235 0.79 THRB (0.66) L3MBTL1THRBATMGAAMEN1
SCHEMBL1128414 0.79 THRB (0.66) L3MBTL1THRBATMGAAMEN1
SCHEMBL8367374 0.79 THRB (0.66) L3MBTL1THRBATMGAAMEN1
SCHEMBL5571829 0.79 EPHX2 (0.57)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7053105-B2 Farnesyl transferase inhibiting quinoline and quinazoline derivatives as farnesyl transferase inhibitors JANSSEN PHARMACEUTICA, N.V. (BE) 2006-05-30 US claimed
EP-1322635-B1 FARNESYL TRANSFERASE INHIBITING QUINOLINE AND QUINAZOLINE DERIVATIVES AS FARNESYL TRANSFERASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2006-03-22 EP claimed
US-20030203904-A1 Farnesyl transferase inhibiting quinoline and quinazoline derivatives as farnesyl transferase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2003-10-30 US claimed
EP-2629771-B1 USE OF PI3K INHIBITORS FOR THE TREATMENT OF OBESITY, STEATOSIS AND AGEING FUNDACION CENTRO NAC DE INVESTIGACIONES ONCOLOGICAS CARLOS III (ES) 2018-08-08 EP disclosed
WO-2011142359-A1 SPIRO COMPOUND AND DRUG FOR ACTIVATING ADIPONECTIN RECEPTOR 日産化学工業株式会社 (JP) 2011-11-17 WO disclosed
US-7645760-B2 1-(4-Benzyl-piperazin-1-yl)-3-phenyl-propenone derivatives NOVARTIS AG. (CH) 2010-01-12 US disclosed
US-20070238734-A1 JNK INHIBITORS SANOLI-AVENTIS (FR) 2007-10-11 US disclosed
US-20060173004-A1 1-(4-Benzyl-piperazin-1-yl)-3-phenyl-propenone derivatives NOVARTIS AG (CH) 2006-08-03 US disclosed
US-7053105-B2 Farnesyl transferase inhibiting quinoline and quinazoline derivatives as farnesyl transferase inhibitors JANSSEN PHARMACEUTICA, N.V. (BE) 2006-05-30 US disclosed
EP-1322635-B1 FARNESYL TRANSFERASE INHIBITING QUINOLINE AND QUINAZOLINE DERIVATIVES AS FARNESYL TRANSFERASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2006-03-22 EP disclosed
US-20030203904-A1 Farnesyl transferase inhibiting quinoline and quinazoline derivatives as farnesyl transferase inhibitors JANSSEN PHARMACEUTICA N.V. (BE) 2003-10-30 US disclosed
EP-0706532-B1 Peptides having endothelin antagonictic activity,their preparation and pharmaceutical compositions FUJISAWA PHARMACEUTICAL CO (JP) 2000-02-02 EP disclosed
US-5888972-A ENDOTHELIN ANTAGONIST FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1999-03-30 US disclosed
EP-0457195-B1 Peptides having endothelin antagonist activity, a process for preparation thereof and pharmaceutical compositions comprising the same FUJISAWA PHARMACEUTICAL CO (JP) 1998-04-15 EP disclosed
US-5656604-A HYPOTENSIVE AGENT; ENDOTHELIN ANTAGONIST FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1997-08-12 US disclosed
EP-0706532-A1 NEW COMPOUND AND ITS PREPARATION FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1996-04-17 EP disclosed
US-5430022-A Endothelin antagonists; hypotensive agents; treatment for angina pectoris, brain disorders, asthma, renal failure FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1995-07-04 US disclosed
WO-1995000537-A1 NEW COMPOUND AND ITS PREPARATION FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1995-01-05 WO disclosed
US-5284828-A Hypotensive agents FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 1994-02-08 US disclosed
EP-0457195-A2 Peptides having endothelin antagonist activity, a process for preparation thereof and pharmaceutical compositions comprising the same FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1991-11-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030203904-A1 Farnesyl transferase inhibiting quinoline and quinazoline derivatives as farnesyl transferase inhibitors FNTA, FNTB, RABGGTB L3MBTL1 2230/4885THRB 1915/4885ATM 3525/4885
US-20070238734-A1 JNK INHIBITORS MAP3K7, MAPKAPK2, MAPK7 L3MBTL1 1498/4885THRB 1163/4885ATM 499/4885
US-20060173004-A1 1-(4-Benzyl-piperazin-1-yl)-3-phenyl-propenone derivatives CCR1, CCR3, CCR4 L3MBTL1 2266/4885THRB 2246/4885ATM 3262/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.